Increased levels of fatty acids contributed to induction of hepatic CYP3A4 activity induced by diabetes - In vitro evidence from HepG2 cell and Fa2N-4 cell lines

Journal of Pharmacological Sciences

Volumn 124, Issue 4, 2014, Pages 433-444

  Hu, Nan ^a,b   Hu, Mengyue ^a   Duan, Ru ^a   Liu, Can ^a   Guo, Haifang ^a   Zhang, Mian ^a   Yu, Yunli ^a   Wang, Xinting ^a   Liu, Li ^a   Liu, Xiaodong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

Author keywords

CYP3A4; Diabetes; Fa2N 4; Fatty acid; HepG2

Indexed keywords

CHOLESTEROL; CYTOCHROME P450 3A4; FATTY ACID; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; MESSENGER RNA; OLEIC ACID; PALMITIC ACID; PROTEIN KINASE C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; CYP3A4 GENE; DIABETES MELLITUS; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME REGULATION; GENE EXPRESSION; IN VITRO STUDY; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; CELL LINE; CYTOCHROME P-450 CYP3A; DIABETES MELLITUS, EXPERIMENTAL; ENZYME INDUCTION; FATTY ACIDS; GENE EXPRESSION; HEP G2 CELLS; HEPATOCYTES; HUMANS; LIVER; RATS; RNA, MESSENGER; STREPTOZOCIN; UP-REGULATION;

EID: 84899511548     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.13212FP     Document Type: Article

References (68)

1. Barnett CR, Gibson GG, Wolf CR, Flatt PR, Ioannides C. Induction of cytochrome P450III and P450IV family proteins in streptozotocin-induced diabetes. Biochem J. 1990;268:765-769. (Pubitemid 20196966)
2. Baek HW, Bae SK, Lee MG, Sohn YT. Pharmacokinetics of chlorzoxazone in rats with diabetes: Induction of CYP2E1 on 6-hydroxychlorzoxazone formation. J Pharm Sci. 2006;95: 2452-2462. (Pubitemid 44726385)
3. Borbas T, Benko B, Dalmadi B, Szabo I, Tihanyi K. Insulin in flavin-containing monooxygenase regulation. Flavin-containing monooxygenase and cytochrome P450 activities in experimental diabetes. Eur J Pharm Sci. 2006;28:51-58.
4. Kim YC, Lee AK, Lee JH, Lee I, Lee DC, Kim SH, et al. Pharmacokinetics of theophylline in diabetes mellitus rats: induction of CYP1A2 and CYP2E1 on 1,3-dimethyluric acid formation. Eur J Pharm Sci. 2005;26:114-123. (Pubitemid 41097268)
5. Liu H, Liu L, Li J, Mei D, Duan R, Hu N, et al. Combined contributions of impaired hepatic CYP2C11 and intestinal breast cancer resistance protein activities and expression to increased oral glibenclamide exposure in rats with streptozotocin-induced diabetes mellitus. Drug Metab Dispos. 2012;40:1104-1112.
6. Hu N, Xie S, Liu L, Wang X, Pan X, Chen G, et al. Opposite effect of diabetes mellitus induced by streptozotocin on oral and intravenous pharmacokinetics of verapamil in rats. Drug Metab Dispos. 2011;39:419-425.
7. Chen GM, Hu N, Liu L, Xie SS, Wang P, Li J, et al. Pharmacokinetics of verapamil in diabetic rats induced by combination of high-fat diet and streptozotocin injection. Xenobiotica. 2011;41:494-500.
8. Yamazoe Y, Murayama N, Shimada M, Yamauchi K, Kato R. Cytochrome P450 in livers of diabetic rats: regulation by growth hormone and insulin. Arch Biochem Biophys. 1989;268:567-575. (Pubitemid 19049735)
9. Abdelmegeed MA, Carruthers NJ, Woodcroft KJ, Kim SK, Novak RF. Acetoacetate induces CYP2E1 protein and suppresses CYP2E1 mRNA in primary cultured rat hepatocytes. J Pharmacol Exp Ther. 2005;315:203-213. (Pubitemid 41380513)
10. Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol. 2001;281:G1135-G1139.
11. Kenny JR, Chen L, McGinnity DF, Grime K, Shakesheff KM, Thomson B, et al. Efficient assessment of the utility of immortalized Fa2N-4 cells for cytochrome P450 (CYP) induction studies using multiplex quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) and substrate cassette methodologies. Xenobiotica. 2008;38:1500-1517.
12. Lai L, Hao H, Wang Q, Zheng C, Zhou F, Liu Y, et al. Effects of short-term and long-term pretreatment of Schisandra lignans on regulating hepatic and intestinal CYP3A in rats. Drug Metab Dispos. 2009;37:2399-2407.
13. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
14. Miwa H. High-performance liquid chromatographic determination of mono-, poly- and hydroxycarboxylic acids in foods and beverages as their 2-nitrophenylhydrazides. J Chromatogr A. 2000;881:365-385. (Pubitemid 30332220)
15. Liu H, Xu X, Yang Z, Deng Y, Liu X, Xie L. Impaired function and expression of P-glycoprotein in blood-brain barrier of streptozotocin-induced diabetic rats. Brain Res. 2006;1123:245-252.
16. Uehara Y, Miura S, von Eckardstein A, Abe S, Fujii A, Matsuo Y, et al. Unsaturated fatty acids suppress the expression of the ATP-binding cassette transporter G1 (ABCG1) and ABCA1 genes via an LXR/RXR responsive element. Atherosclerosis. 2007;191:11-12.
17. Donato MT, Lahoz A, Castell JV, Gomez-Lechon MJ. Cell lines: a tool for in vitro drug metabolism studies. Curr Drug Metab. 2008;9:1-11. (Pubitemid 351201665)
18. Takeba Y, Matsumoto N, Takenoshita-Nakaya S, Harimoto Y, Kumai T, Kinoshita Y, et al. Comparative study of culture conditions for maintaining CYP3A4 and ATP-binding cassette transporters activity in primary cultured human hepatocytes. J Pharmacol Sci. 2011;115:516-524.
19. Hao M, Ba Q, Yin J, Li J, Zhao Y, Wang H. Deglycosylated ginsenosides are more potent inducers of CYP1A1, CYP1A2 and CYP3A4 expression in HepG2 cells than glycosylated ginsenosides. Drug Metab Pharmacokinet. 2011;26:201-205.
20. Matsubara T, Yoshinari K, Aoyama K, Sugawara M, Sekiya Y, Nagata K, et al. Role of vitamin D receptor in the lithocholic acid-mediated CYP3A induction in vitro and in vivo. Drug Metab Dispos. 2008;36:2058-2063.
21. Medina-Díaz IM, Elizondo G. Transcriptional induction of CYP3A4 by o,p'-DDT in HepG2 cells Toxicol Lett. 2005;157:41-47. (Pubitemid 40410611)
22. Usui T, Saitoh Y, Komada F. Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biol Pharm Bull. 2003;26:510-517. (Pubitemid 39663598)
23. Hewitt NJ, Hewitt P. Phase I and II enzyme characterization of two sources of HepG2 cell lines. Xenobiotica. 2004;34:243-256. (Pubitemid 38478893)
24. Ledet T, Vuust J. Arterial procollagen type I, and type III, and fibronectin: effects of diabetic serum, glucose, insulin, ketone, and growth hormone studied on rabbit aortic myomedial cell cultures. Diabetes. 1980;29:964-970. (Pubitemid 11017922)
25. Ornoy A, Zaken V, Abir R, Yaffe P, Raz I. Effects on rat embryos of culture in serum of women with gestational diabetes. Toxicol In Vitro. 1995;9:643-651.
26. Munzel D, Lehle K, Haubner F, Schmid C, Birnbaum DE, Preuner JG. Impact of diabetic serum on endothelial cells: an in-vitro-analysis of endothelial dysfunction in diabetes mellitus type 2. Biochem Biophys Res Commun. 2007;362:238-244. (Pubitemid 47332396)
27. Liu X, Jing XY, Jin S, Li Y, Liu L, Yu YL, et al. Insulin suppresses the expression and function of breast cancer resistance protein in primary cultures of rat brain microvessel endothelial cells. Pharmacol Rep. 2011;63:487-493.
28. Shimojo N, Ishizaki T, Imaoka S, Funae Y, Fujii S, Okuda K. Changes in amounts of cytochrome P450 isozymes and levels of catalytic activities in hepatic and renal microsomes of rats with streptozocin-induced diabetes. Biochem Pharmacol. 1993;46:621-627. (Pubitemid 23262955)
29. Woodcroft KJ, Novak RF. Insulin effects on CYP2E1, 2B, 3A, and 4A expression in primary cultured rat hepatocytes. Chem Biol Interact. 1997;107:75-91. (Pubitemid 27509002)
30. Woodcroft KJ, Novak RF. Insulin differentially affects xenobiotic-enhanced, cytochrome P-450 (CYP)2E1, CYP2B, CYP3A, and CYP4A expression in primary cultured rat hepatocytes. J Pharmacol Exp Ther. 1999;289:1121-1127. (Pubitemid 29191274)
31. Chandrasekaran K, Swaminathan K, Chatterjee S, Dey A. Apoptosis in HepG2 cells exposed to high glucose. Toxicol In Vitro. 2010;24:387-396.
32. Buchholz J, Strother A, Fraser IM. Effect of glucose administration on various rat hepatic constituents and on the spectral binding of hexobarbital and methadone to rat hepatic cytochrome P450. Pharmacology. 1989;38:129-136. (Pubitemid 19083053)
33. Kappas A, Anderson KE, Conney AH, Alvares AP. Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man. Clin Pharmacol Ther. 1976;20:643-653. (Pubitemid 8020943)
34. Tsai SH, Hein TW, Kuo L, Yang VC. High glucose impairs EDHF-mediated dilation of coronary arterioles via reduced cytochrome P450 activity. Microvasc Res. 2011;82:356-363.
35. Hirunpanich V, Sethabouppha B, Sato H. Inhibitory effects of saturated and polyunsaturated fatty acids on the cytochrome P450 3A activity in rat liver microsomes. Biol Pharm Bull. 2007;30:1586-1588. (Pubitemid 47282214)
36. Yao HT, Chang YW, Lan SJ, Chen CT, Hsu JT, Yeh TK. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Life Sci. 2006;79:2432-2440. (Pubitemid 44781104)
37. Donato MT, Lahoz A, Jimenez N, Perez G, Serralta A, Mir J, et al. Potential impact of steatosis on cytochrome P450 enzymes of human hepatocytes isolated from fatty liver grafts. Drug Metab Dispos. 2006;34:1556-1562. (Pubitemid 44285398)
38. Yao HR, Liu J, Plumeri D, Cao YB, He T, Lin L, et al. Lipotoxicity in HepG2 cells triggered by free fatty acids. Am J Transl Res. 2011;3:284-291.
39. Lam JL, Jiang Y, Zhang T, Zhang EY, Smith BJ. Expression and functional analysis of hepatic cytochromes P450, nuclear receptors, and membrane transporters in 10- and 25-week-old db/db mice. Drug Metab Dispos. 2010;38:2252-2258.
40. Choi YH, Lee DC, Lee I, Lee MG. Changes in metformin pharmacokinetics after intravenous and oral administration to rats with short-term and long-term diabetes induced by streptozotocin. J Pharm Sci. 2008;97:5363-5375.
41. Irizar A, Barnett CR, Flatt PR, Ioannides C. Defective expression of cytochrome P450 proteins in the liver of the genetically obese Zucker rat. Eur J Pharmacol. 1995;293:385-393. (Pubitemid 3006681)
42. Fisher CD, Jackson JP, Lickteig AJ, Augustine LM, Cherrington NJ. Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis. Arch Toxicol. 2008;82:959-964.
43. Buechler C, Weiss TS. Does hepatic steatosis affect drug metabolizing enzymes in the liver? Curr Drug Metab. 2011;12:24-34.
44. Zangar RC, Novak RF. Effects of fatty acids and ketone bodies on cytochromes P450 2B, 4A, and 2E1 expression in primary cultured rat hepatocytes. Arch Biochem Biophys. 1997;337:217-224. (Pubitemid 27198185)
45. Oh SJ, Choi JM, Yun KU, Oh JM, Kwak HC, Oh JG, et al. Hepatic expression of cytochrome P450 in type 2 diabetic Goto-Kakizaki rats. Chem Biol Interact. 2012;195:173-179.
46. Thummel KE, Schenkman JB. Effects of testosterone and growth hormone treatment on hepatic microsomal P450 expression in the diabetic rat. Mol Pharmacol. 1990;37:119-129. (Pubitemid 20038459)
47. Tan SH, Shui G, Zhou J, Li JJ, Bay BH, Wenk MR, et al. Induction of autophagy by palmitic acid via protein kinase C-mediated signaling pathway independent of mTOR (mammalian target of rapamycin). J Biol Chem. 2012;287:14364-14376.
48. Couplan E, Le Cann M, Le Foll C, Corporeau C, Blondel M, Delarue J. Polyunsaturated fatty acids inhibit PI3K activity in a yeast-based model system. Biotechnol J. 2009;4:1190-1197.
49. Boden G, She P, Mozzoli M, Cheung P, Gumireddy K, Reddy P, et al. Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver. Diabetes. 2005;54:3458-3465. (Pubitemid 43334336)
50. Guo P, Kai Q, Gao J, Lian ZQ, Wu CM, Wu CA, et al. Cordycepin prevents hyperlipidemia in hamsters fed a high-fat diet via activation of AMP-activated protein kinase. J Pharmacol Sci. 2010;113:395-403.
51. Kim JE, Kim YW, Lee IK, Kim JY, Kang YJ, Park SY. AMP-activated protein kinase activation by 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR) inhibits palmitate-induced endothelial cell apoptosis through reactive oxygen species suppression. J Pharmacol Sci. 2008;106:394-403.
52. Woodcroft KJ, Hafner MS, Novak RF. Insulin signaling in the transcriptional and posttranscriptional regulation of CYP2E1 expression. Hepatology. 2002;35:263-273. (Pubitemid 34106364)
53. Abdelmegeed MA, Carruthers NJ, Woodcroft KJ, Kim SK, Novak RF. Acetoacetate induces CYP2E1 protein and suppresses CYP2E1 mRNA in primary cultured rat hepatocytes. J Pharmacol Exp Ther. 2005;315:203-213. (Pubitemid 41380513)
54. Gu X, Ke S, Liu D, Sheng T, Thomas PE, Rabson AB, et al. Role of NF-kappaB in regulation of PXR-mediated gene expression: a mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents. J Biol Chem. 2006;281:17882-17889. (Pubitemid 44035587)
55. Zangar RC, Bollinger N, Verma S, Karin NJ, Lu Y. The nuclear factor-kappa B pathway regulates cytochrome P450 3A4 protein stability. Mol Pharmacol. 2008;73:1652-1658. (Pubitemid 351724354)
56. Ragheb R, Shanab GM, Medhat AM, Seoudi DM, Adeli K, Fantus IG. Free fatty acid-induced muscle insulin resistance and glucose uptake dysfunction: evidence for PKC activation and oxidative stress-activated signaling pathways. Biochem Biophys Res Commun. 2009;389:211-216.
57. Ajuwon KM, Spurlock ME. Palmitate activates the NF-kappaB transcription factor and induces IL-6 and TNFalpha expression in 3T3-L1 adipocytes. J Nutr. 2005;135:1841-1846. (Pubitemid 41099739)
58. Mugabo Y, Mukaneza Y, Renier G. Palmitate induces C-reactive protein expression in human aortic endothelial cells. Relevance to fatty acid-induced endothelial dysfunction. Metabolism. 2011;60:640-648.
59. Lee MS, Choi SE, Ha ES, An SY, Kim TH, Han SJ, et al. Fibroblast growth factor-21 protects human skeletal muscle myotubes from palmitate-induced insulin resistance by inhibiting stress kinase and NF-kappaB. Metabolism. 2012;61:1142-1151.
60. Rahman SM, Qadri I, Janssen RC, Friedman JE. Fenofibrate and PBA prevent fatty acid-induced loss of adiponectin receptor and pAMPK in human hepatoma cells and in hepatitis C virus-induced steatosis. J Lipid Res. 2009;50:2193-2202.
61. Rahman SM, Qadri I, Janssen RC, Friedman JE. Fenofibrate and PBA prevent fatty acid-induced loss of adiponectin receptor and pAMPK in human hepatoma cells and in hepatitis C virus-induced steatosis. J Lipid Res. 2009;50:2193-2202.
62. Joshi-Barve S, Barve SS, Amancherla K, Gobejishvili L, Hill D, Cave M, et al. Palmitic acid induces production of proinflammatory cytokine interleukin-8 from hepatocytes. Hepatology. 2007;46:823-830. (Pubitemid 47436129)
63. Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C - dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes. 2000;49:1939-1945.
64. Hebbachi A, Saggerson D. Acute regulation of 5′-AMP-activated protein kinase by long-chain fatty acid, glucose and insulin in rat primary adipocytes. Biosci Rep. 2013;33:71-82.
65. Wang Q, Cheng XL, Zhang DY, Gao XJ, Zhou L, Qin XY, et al. Tectorigenin Attenuates Palmitate-Induced Endothelial Insulin Resistance via Targeting ROS-Associated Inflammation and IRS-1 Pathway. PLoS One. 2013;8:e66417.
66. Wei CD, Li Y, Zheng HY, Sun KS, Tong YQ, Dai W, et al. Globular adiponectin protects H9c2 cells from palmitate-induced apoptosis via Akt and ERK1/2 signaling pathways. Lipids Health Dis. 2012;11:135.
67. Yun MR, Lee JY, Park HS, Heo HJ, Park JY, Bae SS, et al. Oleic acid enhances vascular smooth muscle cell proliferation via phosphatidylinositol 3-kinase/Akt signaling pathway. Pharmacol Res. 2006;54:97-102. (Pubitemid 44038381)
68. Liao CC, Ou TT, Huang HP, Wang CJ. The inhibition of oleic acid induced hepatic lipogenesis and the promotion of lipolysis by Caffeic acid via up-regulation of AMPK. J Sci Food Agric. 2013. In press.